PDCD1 and non-small cell lung carcinoma: In an observational study, Cantini et al. [41] treated 253 patients with malignant pleural mesothelioma or advanced NSCLC with PD-1 inhibitors; the previous use of statins was associated with a better response and progression-free survival.